Activation of dendritic cells by local ablation of hepatocellular carcinoma

被引:130
作者
Ali, MY
Grimm, CF
Ritter, M
Mohr, L
Allgaier, HP
Weth, R
Bocher, WO
Endrulat, K
Blum, HE
Geissler, M
机构
[1] Univ Hosp Freiburg, Dept Med 2, D-79106 Freiburg, Germany
[2] Univ Hosp Mainz, Dept Med, Mainz, Germany
关键词
human; CTL; dendritic cells; tolerance; cytokines;
D O I
10.1016/j.jhep.2005.04.016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Local ablation methods are an effective treatment for hepatocellular carcinoma (HCC). The rate of recurrence or development of intra-hepatic metastases may be lowered by antitumoral immune responses. Since HCCs are in general only weakly immunogenic, cell injury induced by local tumor ablation (PEI/RFTA) may increase HCC immunogenicity and may release endogenous adjuvants that activate dendritic cells (DC). The aim of the study, therefore, was the analysis whether PEI or RFTA induced injury results in an adjuvant effect for immune responses to HCCs. Methods: Eight HCC patients were treated with PEI or RFTA and serially analyzed for 4 weeks. Plasmocytoid (PDC) and myeloid dendritic cells (MDC) were analyzed directly ex vivo and in vitro using FACS and proliferation assays. Results: HCC ablation induced a functional transient activation of MDC but not of PDC associated with increased serum levels of TNF-alpha and IL-1 beta. Conclusions: These findings suggest that the combination of PEI or RFTA and active antigen specific immunotherapeutic approaches using DCs is a promising approach for the induction of sustained antitumoral immune responses aiming at the reduction of tumor recurrence and metastases in HCC patients. (c) 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:817 / 822
页数:6
相关论文
共 26 条
[1]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[2]   T cell responses to HLA-A*0201-restricted peptides derived from human α fetoprotein [J].
Butterfield, LH ;
Meng, WS ;
Koh, A ;
Vollmer, CM ;
Ribas, A ;
Dissette, VB ;
Faull, K ;
Glaspy, JA ;
McBride, WH ;
Economou, JS .
JOURNAL OF IMMUNOLOGY, 2001, 166 (08) :5300-5308
[3]  
Butterfield LH, 1999, CANCER RES, V59, P3134
[4]   Natural adjuvants: Endogenous activators of dendritic cells [J].
Gallucci, S ;
Lolkema, M ;
Matzinger, P .
NATURE MEDICINE, 1999, 5 (11) :1249-1255
[5]   Immunotherapy directed against α-fetoprotein results in autoimmune liver disease during liver regeneration in mice [J].
Geissler, M ;
Mohr, L ;
Weth, R ;
Köhler, G ;
Grimm, CF ;
Krohne, TU ;
Von Weizsäcker, F ;
Blum, HE .
GASTROENTEROLOGY, 2001, 121 (04) :931-939
[6]   Mouse α-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice [J].
Grimm, CF ;
Ortmann, D ;
Mohr, L ;
Michalak, S ;
Krohne, TU ;
Meckel, S ;
Eisele, S ;
Encke, J ;
Blum, HE ;
Geissler, M .
GASTROENTEROLOGY, 2000, 119 (04) :1104-1112
[7]  
Hager ED, 1999, ANTICANCER RES, V19, P3403
[8]   Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein [J].
Hanke, P ;
Rabe, C ;
Serwe, M ;
Böhm, S ;
Pagenstecher, C ;
Sauerbruch, T ;
Caselmann, WH .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 (08) :949-955
[9]   Phenotypic analysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver diseases [J].
Kunitani, H ;
Shimizu, Y ;
Murata, H ;
Higuchi, K ;
Watanabe, A .
JOURNAL OF HEPATOLOGY, 2002, 36 (06) :734-741
[10]  
LIVRAGHI T, 1992, ITAL J GASTROENTEROL, V24, P72